Regulatory Grade Oncology RWD
THE COTA DIFFERENCE:
- Our standard datasets include more elements than our competitors
- COTA’s depth of data is unmatched
- 50/50 mix o academic and community data sources
- Tech supported human abstraction creates the highest quality and most complete RWD
- Led by oncologists who inform our curation methodologies
- 1 of 2 oncology RWD companies with regulatory grade data
Why use Real-World Data?
At COTA, we curate regulatory-grade oncology RWD with the most relevance for our life sciences and provider partners, whether that involves supporting regulatory filings or research questions. We cannot unlock the full value of RWD without the highest-quality collection and curation methodology, and we are powering a revolution in the development of new cancer therapies to bring clarity to cancer care.
How we define regulatory-grade data:
Provenance
- COTA oversees the entire process from abstraction of raw data to final delivery of curated RWD
- Traceability of all our data: where it originates, the transformations applied, and QA checks along the way
- Allowance of full auditability by regulators and other stakeholders
Relevance
The right cohorts after applying inclusion/exclusion criteria at the right volumes
Representativeness across real-world and clinical trial populations
Coverage across geographies of interest
Fidelity
- Faithful representation of the original clinical data documented in EHR
- Technology-enabled human abstraction leveraged to understand and capture clinical nuances
- Accuracy of capture ensured through documented, multi-step QA/QC process
We have a responsibility to drive the use of RWD by consistently improving our data and demonstrating its utility. Our data has been used to support FDA and EMA submissions, explain care patterns, understand patient outcomes, and much more – and we anticipate the number of use cases to multiply in the coming years as RWD is explored and leveraged by more and more innovators in the industry.
Interested in learning more about how we can transform cancer care together?
